286 related articles for article (PubMed ID: 25063763)
1. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
Modi Y; Shaaban H; Gauchan D; Maroules M
J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
[TBL] [Abstract][Full Text] [Related]
3. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
4. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
Ramadan H; Duong VH; Al Ali N; Padron E; Zhang L; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S64-6. PubMed ID: 27521328
[TBL] [Abstract][Full Text] [Related]
6. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
[No Abstract] [Full Text] [Related]
7. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
Gauchan D; Shaaban H; Gedeon D; Maroules M
Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
[No Abstract] [Full Text] [Related]
8. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
[No Abstract] [Full Text] [Related]
9. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Jolliffe E; Romeril K
Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
[TBL] [Abstract][Full Text] [Related]
10. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K
Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016
[No Abstract] [Full Text] [Related]
11. Eltrombopag in thrombocytopenia.
Lawson A
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
[No Abstract] [Full Text] [Related]
12. Eltrombopag for the treatment of immune thrombocytopenia.
Cheng G
Expert Rev Hematol; 2011 Jun; 4(3):261-9. PubMed ID: 21671710
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
14. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag for treatment of thrombocytopenia-associated disorders.
Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
17. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
[TBL] [Abstract][Full Text] [Related]
18. Immune thrombocytopenic purpura--from agony to agonist.
Schwartz RS
N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
[No Abstract] [Full Text] [Related]
19. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
